Pyrrolotriazinone as an underexplored scaffold in drug discovery - CEA - Commissariat à l’énergie atomique et aux énergies alternatives Accéder directement au contenu
Article Dans Une Revue Pharmaceuticals Année : 2021

Pyrrolotriazinone as an underexplored scaffold in drug discovery

Résumé

Heterocyclic amino derivatives have been extensively synthesized and validated as potent bioactive compounds, and nowadays, numerous marketed drugs share these scaffolds, from very simple structures (monoamino, monocyclic compounds) to much more complex molecules (polycyclic derivatives with two or more nitrogen atoms within the (fused) rings). In a constant quest for new chemical entities in drug discovery, a few novel heterocycles have emerged in recent years as promising building blocks for the obtainment of bioactive modulators. In this context, pyrrolotriazinones have attracted attention, and some show promising biological activities. Here, we offer an extensive review of pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one and pyrrolo[1,2-d][1,2,4]triazin-4(3H)-one, describing their biological properties en route to drug discovery.

Domaines

Chimie
Fichier principal
Vignette du fichier
pharmaceuticals-14-01275-v2.pdf (2.55 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

cea-04352650 , version 1 (02-02-2024)

Identifiants

Citer

Tony Ge, Jean-Christophe Cintrat. Pyrrolotriazinone as an underexplored scaffold in drug discovery. Pharmaceuticals, 2021, 14 (12), pp.1275. ⟨10.3390/ph14121275⟩. ⟨cea-04352650⟩
8 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More